Latest News
BioAgilytix Acquires Contract Research Organisation Cambridge Biomedical
Friday 08 November 2019

8 November 2019 - North Carolina, US-based bioanalytical testing services company BioAgilytix has acquired Massachusetts, US-based contract research organisation (CRO) Cambridge Biomedical, the company said.
Terms of the transaction were not disclosed.
The transaction expands BioAgilytix's global footprint into the heart of the world's major biotech centre, and adds further capacity by joining Cambridge Biomedical's CLIA-certified, CAP-accredited, and GLP-compliant facility with its GxP laboratories in Durham, North Carolina and Hamburg, Germany.
It grows BioAgilytix's premier team to more than 400 employees worldwide, bringing on board Cambridge Biomedical's seasoned bioanalytical scientists to complement and further enhance BioAgilytix's world-class expertise in biomarkers, immunogenicity, cell-based assays, and pharmacokinetics to support all phases of biologics development.
BioAgilytix is a leading bioanalytical testing laboratory specialising in large molecule bioanalysis. BioAgilytix provides biomarker, immunogenicity, cell-based assay, and PK services supporting the development and release testing of biologics across a number of industries and disease states.
Cambridge Biomedical serves the diverse requirements of the biopharmaceutical/pharmaceutical and diagnostic markets, utilising its multi-platform laboratory science capabilities and state-of-the-art systems and procedures to deliver timely, accurate results.
Cambridge Biomedical was represented by Fairmount Partners throughout this transaction.
Date Published: 08/11/2019
Target: Cambridge Biomedical
Country: USA
Sector: Pharmaceuticals
Type: Corporate acquisition
Status: Closed
Buyer: BioAgilytix
Terms of the deal were not disclosed